Unia Europejska

Prof. dr hab. Piotr Mariusz Skowron (University of Gdansk) has received National Center for Science (NCN) grant in the amount of 2,197,200..

The DNA FACE™ concept has been successfully used to develop prototype pro-regenerative drug. The EP 3.549.947.B1 patent is a result of long.

One of the leading current trends in technology is the miniaturization of devices to the microscale and nanoscale. The highly advanced...

Bacteriophages associated with thermophiles are gaining increased attention due to their pivotal roles...

One of current trends in medical treatment is developing targeted therapeutic interventions against capsular bacteria. The publication...

Zamawiający BioVentures Institute Sp. z o.o informuje, że w wyniku przeprowadzonego postępowania na usługę: Opracowanie technologii...

BioVentures Institute Sp. z o.o, jako podmiot realizujący projekt współfinansowany z Europejskiego Funduszu Rozwoju Regionalnego na...

This publication is a result of long-term scientific cooperation and partnership between BioVentures Institute, University of Gdańsk,...

BioVentures Institute Sp. z o.o. otrzymała dofinansowanie w ramach programu "Granty B+R dla przedsiębiorstw"

This publication is a result of long-term scientific cooperation and partnership between BioVentures Institute, University of Gdańsk,...

The DNA FACE™ concept has been successfully used to develop prototype pro-regenerative drug. The PL 240667 patent is a result...

This publication is a result of long-term scientific cooperation and partnership between BioVentures Institute, University of Gdańsk,...

The National Centre for Research and Development grant TECHMATSTRATEG2/410747/11/NCBR/2019 (2019-2022) to the Consortium led by...

The publication reviewing potential and used by BioVentures Institute thermophilic bacteriophages and Virus-Like-Particles (VLPs)...

The vaccine has been purified, analysed using a number of techniques, including electrophoresis, LC-MS, Western blotting and was...

The DNA-FACE™ concept of construction of ‘artificial’, concatemeric protein with a vaccine functionality has been used to construct an...

Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...

Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...

The National Centre for Research and Development grant TECHMATSTRATEG-III/0042/2019 (2020-2023) received by the Institute...

Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...

Detailed laboratory protocols, concerning the patented BioVentures Institute genetic engineering and protein functional programming,...

We have been informed by Chineese Patent Office that our patent application no 201580028495.1, concerning our break-through recombinant...

Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...

Scientific publication in the area of industrial enzymes. A novel proteinase Onygena, an improved alternative to the ‘workhorse’ of...

We have been informed by Israeli Patent Office that our patent application no 248011, concerning our break-through recombinant DNA...

Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...

We have been informed by Indian Patent Office that our patent application no 201647039411, concerning our break-through recombinant DNA...

More technical details, concerning the patented BioVentures Institute genetic engineering and protein functional programming,...

The patented BioVentures Institute genetic engineering and protein functional programming, construction and biosynthesis technology,...

Our break-through recombinant DNA biotechnology for the construction of new generation vaccines, biologics, biosymilars, industrial and...

New scientific publication, defining a new bacteriophage genus TP84 virus. The paper describes monographic work on TP-84 bacteriophage...

Our company and team members are environmentally conscious. BioVentures Institute’s patented technology has a potentially high impact on...

Our company and team members are environmentally conscious. BioVentures Institute patented technology has potentially high impact on the...

BioVentures InstituteSp. z o.o. continues a long term cooperation with University of Gdansk and New England Biolabs Ltd. (USA), a world...

The new grant STRATEGMED TARGETTELO in the amount of 19 654 385.00 PLN issued by the National Center for Research and Development was...

BioVentures Institute Sp. z o.o. has extended the international PCT patent application no WO 2015162560 A1, covering the technology of...

BioVentures Institute established business relationships with several Israeli companies, as well as with the Israeli Ministry of Regional...

Cooperation in the area of engineering of enzyme performance for biotechnology purposes between BioVentures Institute Sp. z o. o. and ...

Barentzymes AS, a Norwegian biotechnology company (part of Fluenta holding) has signed a long term cooperation agreement with BioVentures...

Professor Piotr Skowron received the 1st award granted by the Pomeranian Employers Association in the category “Primum Cooperatio” i.e....

BioVentures Institute Sp. z o.o. filed an international patent application (PCT). Title of application: „A method of obtaining a...

In cooperation with the University of Gdańsk, BioVentures Institute Sp. z o.o. has established funds and applied research programmes for...

Scientists from BioVentures Institute Sp. z o.o. continue their cooperation with theUniversity of Gdansk in the area of regenerative...

Piotr Skowron received the professor title in biological sciences. On July 28th, after receiving positive reviews and a decision from...

Cooperation in the area of gene cloning and engineering of enzymes for biotechnology applications between BioVentures Institute Sp. z...

BioVentures Institute Sp. z o.o. has accepted a venture capital entry by SATUS Venture Capital and Jagiellonian Centre of Innovation...

The ongoing scientific cooperation between BioVentures Institute Sp. z o.o., Thermo Fisher Scientific and Department of Molecular...

INVESTIN programme in cooperation with BioVentures Institute Sp. z o.o. has established two funds for advanced molecular biotechnology...

BioVentures Institute Sp. z o.o. received funding from the European Union (EU) via the National Centre for Research and Development...

The scientific cooperation between BioVentures Institute Sp. z o.o., Thermo Fisher Scientific and Department of Environmental Molecular...